A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Last updated: March 5, 2024
Sponsor: Vanda Pharmaceuticals
Overall Status: Active - Recruiting

Phase

2

Condition

Sjogren's Syndrome

Dry Eye Disease

Dry Eyes

Treatment

VSJ-110

Placebo

Clinical Study ID

NCT06296966
VP-VSJ-110-2201
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Be at least 18 years of age of either gender and any race.
  • Provide written informed consent and sign the HIPAA form.
  • Be willing and able to follow all instructions and attend all study visits.

Exclusion

Exclusion Criteria:

  • Use of any of the disallowed medications during the washout and study period.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: VSJ-110
Phase: 2
Study Start date:
February 29, 2024
Estimated Completion Date:
July 31, 2024

Connect with a study center

  • Vanda Investigational Site

    Andover, Massachusetts 01810
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.